US 2003/0195237 A1 · Gastrin and cholecystokinin receptor lignads (iv)

Abstract

1 Compounds of the formula (I) or (II) and their pharmaceutically acceptable salts are ligands at gastrin and/or chole-cystokinin receptors. n is from 1 to 4; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; Z is —(NR5)a—CO—(NR6)b-(wherein a is 0 or 1, b is 0 or 1, and R5 and R6 are independently selected from H, Me, Et, Pr, Bn), —CO—NR5—CH2—CO—NR6—, —CO—O—, —CH2—CH2—, —CH═CH—, CH2—NR6— or a bond; Q is R7V, or(a) wherein R7 is —CH2—; —CH2—; or(b) R7 and R6, together with the nitrogen atom to which R6 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, CH2OH, or a group of the formula —R8U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H; and R8 is a bond; C1 to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamino; —O-(C1 to C3 alkylene)-; —SO2NR9—CHR10—; —CO—NR9CHR10—, R9 and R10 being independently selected from H and methyl; or —NH—(CO)c—CH2—, c being 0 or 1); m is 1 or 2; q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond); Compositions comprising a compound of formula (I) or (II) are also described.

Claims40

Dependent claims

A compound of the formula (I) or (II)

15
wherein
n is from 1 to 4;
R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms;
R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1;
R3 (when n is 1) is selected from H, Me, Et and Pr;
or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond;
or R2 and R3 on the same carbon atom together represent an ═O group;
R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms;
Z is —(NR5)a—CO—(NR6)b— (wherein a is 0 or 1, b is 0 or 1, and R5 and R6 are independently selected from H, Me, Et Pr, Bn), —CO—NR5—CH2—CO—NR6—, —CO—O—, —CH2—CH2—, —CH═CH—, —CH2—NR6— or a bond;
Q is —R7V, or
16
(wherein R7 is —CH2—;
—CH2—CH2—;
or
17
or R7 and R6, together with the nitrogen atom to which R6 is attached, form a piperidine or pyrrolidine ring which is substituted by V;
V is —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R8U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H;
and R8 is a bond;
C1 to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamido;
—O-(C1 to C3 alkylene)-;
—SO2NR9—CHR10—;
—CO—NR9—CHR10—, R9 and R10 being independently selected from H and methyl;
or —NH—(CO)c—CH2—, c being 0 or 1);
T is C1 to C6 hydrocarbyl, —NR11R12 (wherein R11 and R12 are independently selected from H, Me, Et, Pr, Bn), —OMe, —OH, —CH2OH, halogen or trihalomethyl;
m is 1 or 2;
p is from 0 to 3;
and
q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond);
or a pharmaceutically acceptable salt thereof.

27 more elements

Dependencies are inferred from the claim text.

Gastrin and cholecystokinin receptor lignads (iv)

Life of this patent

Gastrin and cholecystokinin receptor lignads (iv)

Life of this patent

Abstract

Claims40